Targeting Th17 cells in autoimmune diseases

Tracking global gene expression responses in T cell differentiation

“…Hence, the effector subtype is called Th 17 and it orchestrates critical roles in facilitating the recruitment of innate immune cells, such as macrophages, to infected tissues. The dysregulation of Th 17 leads to major autoimmune diseases and, on some occasions, cancer (Su et al, 2014;Yang et al, 2014). Although there are numerous works, lately, that characterize novel details about individual factors, large-scale global response studies are still limited.…”

Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

“…5 RORt inhibitors has potential utility in reducing the activity of Th17 cells and therefore can be developed as therapeutic agents for the treatment of Th17-mediated autoimmune diseases. [7][8][9][10][11][12][13] A few small molecule inhibitors against RORt have been reported in literature. 14 Digoxin, 15 SR1001 16 and Ursolic acid 17 were firstly reported to inhibit RORt and ameliorate EAE in mice via intraperitoneal administration.…”

Mutual interaction between BCL6 and microRNAs in T cell differentiation

“…58 Although Th17 cells have been identified as a new CD4 C T subset based on the expression of the critical transcription factor retinoic acid receptor-related orphan receptor-gt (RORgt) and cytokines in the IL-17 family, 59 there is evidence indicating that BCL6 and Ncor2 are also 2 important transcription factors in Th17 cell differentiation. In a recent study, retinoic acid (RA) was shown to induce miRNA-10a expression, which directly targets sequences in the 3 0 -UTR of BCL6 mRNA and downregulates BCL6 expression.…”